Rhelion FY27 Q1 net loss widens to CAD 1.89 million; revenue falls 66.37% to CAD 186,000

• Rhelion posted Q1 fiscal 2027 revenue of CAD 186,000, down 66.37% from a year earlier.
• Net loss widened 80.59% to CAD 1.89 million from Q1 fiscal 2026.
• Adjusted EBITDA loss widened to CAD 1.06 million from CAD 679,000 in the prior-year quarter.
• Cash totaled CAD 2.6 million, short-term investments were CAD 5.02 million, following a roughly CAD 5 million transfer into one-year GICs.
• Quarter capped the Filament acquisition, shifting focus to naturally derived psychedelic R&D, led by psilocybin candidate PEX010; ibogaine program IBEX011 under evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608310839NEWSFILECNPR____20260831_312148_1) on August 31, 2026, and is solely responsible for the information contained therein.